Skye Bioscience Inc (SKYE)

[Vinpat]

I'm not sure why they compared it to Pilocarpine and Timolol other then those seem to be the standard drugs everyone in the sector compares them to. The studies I saw didn't show that Latanoprost to be significantly better than the others and many patients are treated with combos of drops because they lose their effectiveness or work better in combo. Nemus' candidate protects the optic nerve which is critical. Especially in Japan where glaucoma is genetic and usually not caused by IOP. Daily drops will be the thing of the past as implants have been developed and Nemus has already announced that's the method they will eventually use.

Besides the 2 candidates, they also have a MRSA candidate that they've known for years is very effective and they just announced results on it.

They have fewer O/S shares than anyone in the sector and everyone on the OTC needs money and has a going concern.